Skip to main content
Erschienen in: European Radiology 2/2005

01.02.2005 | Cardiac

Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging

verfasst von: A. Hansch, R. Rzanny, J.-P. Heyne, U. Leder, J. R. Reichenbach, W. A. Kaiser

Erschienen in: European Radiology | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

Dilated cardiomyopathy (DCM) is accompanied by an impaired cardiac energy metabolism. The aim of this study was to investigate metabolic ratios in patients with DCM compared to controls by using spectroscopic two-dimensional chemical shift imaging (2D-CSI). Twenty volunteers and 15 patients with severe symptoms (left ventricular ejection fraction, LVEF<30%) and ten patients with moderate symptoms (LVEF>30%) of DCM were investigated. Cardiac 31P MR 2D-CSI measurements (voxel size: 40×40×100 mm3) were performed with a 1.5 T whole-body scanner. Measurement time ranged from 15 min to 30 min. Peak areas and ratios of different metabolites were evaluated, including high-energy phosphates (PCr, ATP), 2,3-diphosphoglycerate (2,3-DPG) and phosphodiesters (PDE). In addition, we evaluated how PCr/ATP ratios correlate with LVEF as an established prognostic factor of heart failure. The PCr/γ-ATP ratio was significantly decreased in patients with moderate and severe DCM and showed a linear correlation with reduced LVEFs. PDE/ATP ratios were significantly increased only in patients with severe DCM as compared to volunteers. Applying 31P MRS with commonly-available 2D-CSI sequences is a valuable technique to evaluate DCM by determining PCr/ATP ratios noninvasively. In addition to reduced PCr/ATP ratios observed in patients suffering from DCM, significantly-increased PDE/ATP ratios were found in patients with severe DCM.
Literatur
1.
Zurück zum Zitat Fatkin D, Graham RM (2002) Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82:945–980 Fatkin D, Graham RM (2002) Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82:945–980
2.
Zurück zum Zitat Bottomley PA (1994) MR spectroscopy of the human heart: the status and the challenges. Radiology 191:593–612 Bottomley PA (1994) MR spectroscopy of the human heart: the status and the challenges. Radiology 191:593–612
3.
Zurück zum Zitat Ingwall JS (1982) Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 242:729–744 Ingwall JS (1982) Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 242:729–744
4.
Zurück zum Zitat Schaefer S, Gober J, Valenza M, Karczmar GS, Matson GB, Camacho SA, Botvinick EH, Massie B, Weiner MW (1988) Nuclear magnetic resonance imaging-guided phosphorus-31 spectroscopy of the human heart. J Am Coll Cardiol 12:1449–1455 Schaefer S, Gober J, Valenza M, Karczmar GS, Matson GB, Camacho SA, Botvinick EH, Massie B, Weiner MW (1988) Nuclear magnetic resonance imaging-guided phosphorus-31 spectroscopy of the human heart. J Am Coll Cardiol 12:1449–1455
5.
Zurück zum Zitat Schaefer S, Massie B, Weiner MW (1989) Magnetic resonance spectroscopy of the heart. Cardiol Clin 7:697–712 Schaefer S, Massie B, Weiner MW (1989) Magnetic resonance spectroscopy of the heart. Cardiol Clin 7:697–712
6.
Zurück zum Zitat Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52–61PubMed Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52–61PubMed
7.
Zurück zum Zitat Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B (1990) In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol 65:1154–1161CrossRef Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B (1990) In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol 65:1154–1161CrossRef
8.
Zurück zum Zitat Auffermann W, Chew WM, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB (1991) Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179:253–259 Auffermann W, Chew WM, Wolfe CL, Tavares NJ, Parmley WW, Semelka RC, Donnelly T, Chatterjee K, Higgins CB (1991) Normal and diffusely abnormal myocardium in humans: functional and metabolic characterization with P-31 MR spectroscopy and cine MR imaging. Radiology 179:253–259
9.
Zurück zum Zitat Masuda Y, Tateno Y, Ikehira H, Hashimoto T, Shishido F, Sekiya M, Imazeki Y, Imai H, Watanabe S, Inagaki Y (1992) High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies—the study using ECG gated MR spectroscopy with a localization technique. Jpn Circ J 56:620–626 Masuda Y, Tateno Y, Ikehira H, Hashimoto T, Shishido F, Sekiya M, Imazeki Y, Imai H, Watanabe S, Inagaki Y (1992) High-energy phosphate metabolism of the myocardium in normal subjects and patients with various cardiomyopathies—the study using ECG gated MR spectroscopy with a localization technique. Jpn Circ J 56:620–626
10.
Zurück zum Zitat Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G (1991) Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122:795–801CrossRef Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G (1991) Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 122:795–801CrossRef
11.
Zurück zum Zitat Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K et al (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86:1810–1818 Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K et al (1992) 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86:1810–1818
12.
Zurück zum Zitat Bottomley PA, Hardy CJ (1992) Proton overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T. Magn Reson Med 24:384–390 Bottomley PA, Hardy CJ (1992) Proton overhauser enhancements in human cardiac phosphorus NMR spectroscopy at 1.5 T. Magn Reson Med 24:384–390
13.
Zurück zum Zitat Loffler R, Sauter R, Kolem H, Haase A, von Kienlin M (1998) Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. J Magn Reson 134:287–299CrossRef Loffler R, Sauter R, Kolem H, Haase A, von Kienlin M (1998) Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. J Magn Reson 134:287–299CrossRef
14.
Zurück zum Zitat Meininger M, Landschuetz W, Beer M, Seyfarth T, Horn M, Pabst T, Haase A, Hahn D, Neubauer S, von Kienlin M (1999) Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 41:657–663 Meininger M, Landschuetz W, Beer M, Seyfarth T, Horn M, Pabst T, Haase A, Hahn D, Neubauer S, von Kienlin M (1999) Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 41:657–663
15.
Zurück zum Zitat Rector TS, Cohn JN (1994) Prognosis in congestive heart failure. Annu Rev Med 45:341–350CrossRef Rector TS, Cohn JN (1994) Prognosis in congestive heart failure. Annu Rev Med 45:341–350CrossRef
16.
Zurück zum Zitat Schaefer S (1990) Clinical nuclear magnetic resonance spectroscopy: insight into metabolism. Am J Cardiol 66:45–50CrossRef Schaefer S (1990) Clinical nuclear magnetic resonance spectroscopy: insight into metabolism. Am J Cardiol 66:45–50CrossRef
17.
Zurück zum Zitat Krahe T, Schindler R, Neubauer S, Ertl G, Horn M, Lackner K (1993) 31P-cardio-MR-spectroscopy in myocardial insufficiency. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 159:64–70 Krahe T, Schindler R, Neubauer S, Ertl G, Horn M, Lackner K (1993) 31P-cardio-MR-spectroscopy in myocardial insufficiency. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 159:64–70
18.
Zurück zum Zitat Schindler R, Krahe T, Neubauer S, Hillenbrand H, Entzeroth C, Horn M, Lackner K, Ertl G (1992) The direct measurement of the spin-grid-relaxation times of phosphorus metabolites in the human myocardium. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 157:452–457 Schindler R, Krahe T, Neubauer S, Hillenbrand H, Entzeroth C, Horn M, Lackner K, Ertl G (1992) The direct measurement of the spin-grid-relaxation times of phosphorus metabolites in the human myocardium. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 157:452–457
19.
Zurück zum Zitat Ye Y, Gong G, Ochiai K, Liu J, Zhang J (2001) High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103:1570–1576 Ye Y, Gong G, Ochiai K, Liu J, Zhang J (2001) High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103:1570–1576
21.
Zurück zum Zitat Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96:2190–2196 Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K (1997) Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96:2190–2196
22.
Zurück zum Zitat van Dobbenburgh JO, Lekkerkerk C, van Echteld CJ, de Beer R (1994) Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T. NMR Biomed 7:218–224 van Dobbenburgh JO, Lekkerkerk C, van Echteld CJ, de Beer R (1994) Saturation correction in human cardiac 31P MR spectroscopy at 1.5 T. NMR Biomed 7:218–224
Metadaten
Titel
Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging
verfasst von
A. Hansch
R. Rzanny
J.-P. Heyne
U. Leder
J. R. Reichenbach
W. A. Kaiser
Publikationsdatum
01.02.2005
Erschienen in
European Radiology / Ausgabe 2/2005
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-004-2504-0

Weitere Artikel der Ausgabe 2/2005

European Radiology 2/2005 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.